We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of TIVA (Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing Postoperative Nausea and Vomiting

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01478165
Recruitment Status : Completed
First Posted : November 23, 2011
Last Update Posted : November 23, 2011
Sponsor:
Information provided by (Responsible Party):

November 21, 2011
November 23, 2011
November 23, 2011
September 2011
November 2011   (Final data collection date for primary outcome measure)
Incidence of postoperative nausea and vomiting [ Time Frame: For 24 hours after surgery ]
Same as current
No Changes Posted
Severity of nausea [ Time Frame: For 24 hours after surgery ]
Same as current
Not Provided
Not Provided
 
Comparison of TIVA (Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing Postoperative Nausea and Vomiting
Comparative Study of TIVA(Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing PONV(Postoperative Nausea and Vomiting)

A total intravenous anesthesia (TIVA) is a useful anesthetic technique that reduces the incidence of postoperative nausea and vomiting (PONV).

Investigator hypothesized the incidence of PONV can be further reduced when palonosetron is added to TIVA.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Postoperative Nausea and Vomiting
  • Drug: Total intravenous anesthesia
    Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
  • Drug: Total intravenous anesthesia plus palonosetron
    Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
  • Placebo Comparator: Tiva group (Group T)
    Intervention: Drug: Total intravenous anesthesia
  • Active Comparator: TIVA plus palonosetron group (Group T+P)
    Intervention: Drug: Total intravenous anesthesia plus palonosetron
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
November 2011
November 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • ASA Physical Status 1 or 2
  • Elective gynaecological laparoscopic surgery of ≥ 1h duration

Exclusion Criteria:

  • Anti-emetics, steroids, or psychoactive medications within 24 h of study initiation
  • Vomiting or retching in the 24 h preceding surgery
  • Cancer chemotherapy within 4 weeks or emetogenic radiotherapy within 8 weeks before study entry
  • Ongoing vomiting from gastrointestinal disease
Sexes Eligible for Study: Female
19 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
 
NCT01478165
OC11MISI0090
Yes
Not Provided
Not Provided
Soo Kyoung Park, Incheon St.Mary's Hospital
Incheon St.Mary's Hospital
Not Provided
Principal Investigator: Soo Kyoung Park Incheon St.Mary's Hospital
Incheon St.Mary's Hospital
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP